Quark Delayed Graft Function Drug Safe in Phase I

Safety data show no dose-limiting toxicities in any cohort, Quark said, supporting the drug's continued development.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.